Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2026 Autoimmune Neurology Conference | Industry Therapeutic Update from Kyverna Therapeutics: Miv-cel CD19 CAR T: Changing Paradigms in Neurologic Autoimmune Disease Care

Friday 08/07/26
05:30 PM - 06:30 PM CDT Add To Calendar
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
General Neurology
This symposium will examine the rationale for CD19-directed CAR T-cell therapies in B cell–driven neurologic autoimmune diseases. Attendees will review emerging clinical data from miv-cel (mivocabtagene autoleucel, formerly KYV-101), an investigational CD19 CAR T-cell therapy, and discuss key considerations relevant to CAR T-cell therapy in neuroautoimmune populations, with a focus on stiff person syndrome and myasthenia gravis.
No CME available
Event Timeline
05:30 PM - 06:30 PM CDT Discussion Industry Therapeutic Update from Kyverna Therapeutics: Miv-cel CD19 CAR T: Changing Paradigms in Neurologic Autoimmune Disease Care
Faculty Disclosures
Dena Grayson Dr. Grayson has received personal compensation for serving as an employee of Kyverna Therapeutics.
Warner Biddle No disclosure on file
Dimitrios Mougiakakos Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyverna Therapeutics. Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Interius Bio. Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AvenCell. Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Beigene. Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kite/Gilead. Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zeneca. Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dimitrios Mougiakakos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie.
Marinos C. Dalakas, MD, FÂ鶹´«Ã½Ó³»­ Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols, . Dr. Dalakas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dysimmune Diseases Foundation. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Â鶹´«Ã½Ó³»­. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurology (TAND). Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink.